JPWO2020175704A1 - - Google Patents

Info

Publication number
JPWO2020175704A1
JPWO2020175704A1 JP2021502667A JP2021502667A JPWO2020175704A1 JP WO2020175704 A1 JPWO2020175704 A1 JP WO2020175704A1 JP 2021502667 A JP2021502667 A JP 2021502667A JP 2021502667 A JP2021502667 A JP 2021502667A JP WO2020175704 A1 JPWO2020175704 A1 JP WO2020175704A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021502667A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020175704A1 publication Critical patent/JPWO2020175704A1/ja
Priority to JP2023102852A priority Critical patent/JP2023112136A/ja
Priority to JP2025024594A priority patent/JP2025075059A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021502667A 2019-02-28 2020-02-28 Pending JPWO2020175704A1 (OSRAM)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023102852A JP2023112136A (ja) 2019-02-28 2023-06-22 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法
JP2025024594A JP2025075059A (ja) 2019-02-28 2025-02-18 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019035603 2019-02-28
JP2019112619 2019-06-18
PCT/JP2020/008527 WO2020175704A1 (ja) 2019-02-28 2020-02-28 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023102852A Division JP2023112136A (ja) 2019-02-28 2023-06-22 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法

Publications (1)

Publication Number Publication Date
JPWO2020175704A1 true JPWO2020175704A1 (OSRAM) 2020-09-03

Family

ID=72239799

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2021502667A Pending JPWO2020175704A1 (OSRAM) 2019-02-28 2020-02-28
JP2021502662A Pending JPWO2020175697A1 (OSRAM) 2019-02-28 2020-02-28
JP2023083174A Pending JP2023096156A (ja) 2019-02-28 2023-05-19 ３，５－二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法
JP2023102852A Pending JP2023112136A (ja) 2019-02-28 2023-06-22 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法
JP2024134396A Pending JP2024152860A (ja) 2019-02-28 2024-08-09 ３，５－二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法
JP2025024594A Pending JP2025075059A (ja) 2019-02-28 2025-02-18 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2021502662A Pending JPWO2020175697A1 (OSRAM) 2019-02-28 2020-02-28
JP2023083174A Pending JP2023096156A (ja) 2019-02-28 2023-05-19 ３，５－二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法
JP2023102852A Pending JP2023112136A (ja) 2019-02-28 2023-06-22 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法
JP2024134396A Pending JP2024152860A (ja) 2019-02-28 2024-08-09 ３，５－二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法
JP2025024594A Pending JP2025075059A (ja) 2019-02-28 2025-02-18 ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法

Country Status (8)

Country Link
US (2) US20220125793A1 (OSRAM)
EP (2) EP3932427A4 (OSRAM)
JP (6) JPWO2020175704A1 (OSRAM)
KR (2) KR20210130774A (OSRAM)
AU (4) AU2020229714B2 (OSRAM)
MA (2) MA55091A (OSRAM)
TW (2) TW202039507A (OSRAM)
WO (2) WO2020175697A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP4470621A3 (en) 2018-03-19 2025-05-07 Taiho Pharmaceutical Co., Ltd. Use of sodium alkyl sulfate
US20220348662A1 (en) * 2019-09-26 2022-11-03 Janssen Pharmaceutica Nv Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
WO2025046272A1 (en) * 2023-08-31 2025-03-06 Taiho Pharmaceutical Co., Ltd. Methods of treating cancer using futibatinib and pembrolizumab

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013108809A1 (ja) * 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩
WO2017150725A1 (ja) * 2016-03-04 2017-09-08 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
JP2018511611A (ja) * 2015-04-03 2018-04-26 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 癌治療のためのｆｇｆｒ／ｐｄ−１併用療法
JP2018519327A (ja) * 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法
JP2018537420A (ja) * 2015-10-23 2018-12-20 株式会社 キャンバス 癌治療のためのｔ細胞活性化及び／又はチェックポイント阻害剤を組み合わせたペプチド及びペプチド模倣物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040004771A (ko) 2002-07-05 2004-01-16 삼광유리공업주식회사 필름 코팅 유리컵 및 그 제조방법
KR101480809B1 (ko) 2012-03-26 2015-01-09 한국화학연구원 리그닌-폴리에스테르 수지 혼합 분말의 제조 방법 및 이에 따라 제조되는 리그닌-폴리에스테르 수지 혼합 분말
WO2015008844A1 (ja) * 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
JP6572561B2 (ja) 2015-03-03 2019-09-11 ダイキン工業株式会社 熱交換器および空気調和機
RU2745707C2 (ru) * 2015-11-23 2021-03-30 Файв Прайм Терапьютикс, Инк. Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
JP6409797B2 (ja) 2016-02-24 2018-10-24 三菱電機株式会社 冷蔵庫

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013108809A1 (ja) * 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩
JP2018511611A (ja) * 2015-04-03 2018-04-26 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 癌治療のためのｆｇｆｒ／ｐｄ−１併用療法
JP2018519327A (ja) * 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法
JP2018537420A (ja) * 2015-10-23 2018-12-20 株式会社 キャンバス 癌治療のためのｔ細胞活性化及び／又はチェックポイント阻害剤を組み合わせたペプチド及びペプチド模倣物
WO2017150725A1 (ja) * 2016-03-04 2017-09-08 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF MORECULAR MEDICINE, vol. 38, JPN6022036154, 2016, pages 3 - 15, ISSN: 0005017131 *

Also Published As

Publication number Publication date
KR20210131387A (ko) 2021-11-02
EP3932425A1 (en) 2022-01-05
JPWO2020175697A1 (OSRAM) 2020-09-03
AU2020229714B2 (en) 2025-02-27
MA55091A (fr) 2022-01-05
AU2025203861A1 (en) 2025-06-19
JP2025075059A (ja) 2025-05-14
JP2023096156A (ja) 2023-07-06
AU2020228514B2 (en) 2025-02-27
US20220125793A1 (en) 2022-04-28
AU2020229714A1 (en) 2021-10-07
AU2020228514A1 (en) 2021-10-07
MA55088A (fr) 2022-01-05
US20220184082A1 (en) 2022-06-16
EP3932425A4 (en) 2022-12-07
JP2024152860A (ja) 2024-10-25
KR20210130774A (ko) 2021-11-01
JP2023112136A (ja) 2023-08-10
AU2025203865A1 (en) 2025-06-19
WO2020175704A1 (ja) 2020-09-03
TW202045182A (zh) 2020-12-16
EP3932427A4 (en) 2022-12-07
WO2020175697A1 (ja) 2020-09-03
EP3932427A1 (en) 2022-01-05
TW202039507A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
BR112019017762A2 (OSRAM)
BR112021008711A2 (OSRAM)
BR112019016141A2 (OSRAM)
AU2020104490A5 (OSRAM)
BR112021013944A2 (OSRAM)
JPWO2020175697A1 (OSRAM)
BR112019016142A2 (OSRAM)
BR112021017234A2 (OSRAM)
BR112021012348A2 (OSRAM)
BR112021013128A2 (OSRAM)
BR112019016136A2 (OSRAM)
BR102020025141B1 (pt) Máquina elétrica girante eletronicamente comutada
BR102020020816B1 (pt) Veículo, e, método para controlar o movimento de ar através de um veículo com uma ventoinha do veículo
BR102020018650B1 (pt) Método para preparar óxido de cálcio usando um forno pré- aquecedor de suspensão de múltiplos estágios
BR102020017390B1 (pt) Bomba multifásica
BR112021026535B1 (pt) MÉTODO DE DECODIFICAÇÃO/CODIFICAÇÃO DE IMAGEM REALIZADO POR UM APARELHO DE DECODIFICAÇÃO/CODIFICAÇÃO DE IMAGEM, MÉTODO DE TRANSMISSÃO DE UM FLUXO DE BITS GERADO POR UM MÉTODO DE CODIFICAÇÃO DE IMAGEM e MEIO DE GRAVAÇÃO LEGÍVEL POR COMPUTADOR NÃO TRANSITÓRIO
BR102020011722B1 (pt) Porta de tela para um pacote de radiadores
BR102020005860B1 (pt) Controle de obstrução para um implemento agrícola
BR112021010564B1 (pt) Sistema de armadilha para animais e método de monitoramento do mesmo
BR112021013470B1 (pt) Conector de acesso sem agulha para facilitar a entrega de instrumento a um conjunto de cateter
BR102020000355B1 (pt) Embreagem que tem dois estágios para aplicar torque variado entre um eixo de entrada e um eixo de saída
BR102019027339B1 (pt) Sistema de aspersão de água e difusor de sistema de aspersão de água
BR102019026542B1 (pt) Sistema para detectar e controlar a posição de spoiler de asa de aeronave
BR102019026215B1 (pt) Sinalizador acústico
BR102019026293B1 (pt) Sistema de aeronave, e, método para transmitir energia de um primeiro componente para um segundo componente

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230322